Wei Lian

1 month ago | nature.com | Yuxiang Ma |Yun Fan |Siqing Fu |Lin Wu |David Sommerhalder |Wei Lian | +2 more

AbstractAntibody–drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker.